Trial reportJournal of internal medicine2005
Metformin improves endothelial function in patients with metabolic syndrome.
Trial report in Journal of internal medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03355469 (Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 167 citations in OpenAlex.
- Cardiovascular Effectiveness and Safety of Antidiabetic Drugs in Patients with Type 2 Diabetes and Peripheral Artery Disease: Systematic Review.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Trial
- Endothelial dysfunction in chronic kidney disease: a clinical perspective.American journal of physiology. Heart and circulatory physiology · 2025Review
- Comprehensive treatment of diabetic endothelial dysfunction based on pathophysiological mechanism.Frontiers in medicine · 2025Review
- Diabetes Mellitus and Cardiovascular Disease: Exploring Epidemiology, Pathophysiology, and Treatment Strategies.Reviews in cardiovascular medicine · 2024Review
- Metformin associates with higher myocardial perfusion reserve and survival in type 2 diabetes mellitus patients.Scientific reports · 2024Article
- Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities.Nature metabolism · 2024Review
- Influence of rutin and its combination with metformin on vascular functions in type 1 diabetes.Scientific reports · 2023Article
- Repurposing Metformin for Vascular Disease.Current medicinal chemistry · 2023Review
- Erectile dysfunction and diabetes: A melting pot of circumstances and treatments.Diabetes/metabolism research and reviews · 2022Review
- Metformin improves skeletal muscle microvascular insulin resistance in metabolic syndrome.American journal of physiology. Endocrinology and metabolism · 2022Article
- Metformin Alleviates LPS-Induced Acute Lung Injury by Regulating the SIRT1/NF-κB/NLRP3 Pathway and Inhibiting Endothelial Cell Pyroptosis.Frontiers in pharmacology · 2022Article
- Hemorheological Parameters in Diabetic Patients: Role of Glucose Lowering Therapies.Metabolites · 2021Article
- Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction.Antioxidants (Basel, Switzerland) · 2021Review
- Impact of glycemic control on the association of endothelial dysfunction and coronary artery disease in patients with type 2 diabetes mellitus.Cardiovascular diabetology · 2021Article
- Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects?Biomedicines · 2020Review
- Metformin as a Potential Agent in the Treatment of Multiple Sclerosis.International journal of molecular sciences · 2020Review
- Effects of Dapagliflozin on Endothelial Dysfunction in Type 2 Diabetes With Established Ischemic Heart Disease (EDIFIED).Journal of the Endocrine Society · 2020Article
- Pleiotropic Activity of Metformin and Its Sulfonamide Derivatives on Vascular and Platelet Haemostasis.Molecules (Basel, Switzerland) · 2019Article
- Obesity and Erectile Dysfunction: From Bench to Clinical Implication.The world journal of men's health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic Syndrome (MS) is associated with impaired endothelial function and increased cardiovascular risk. Insulin resistance is a key feature of MS and plays an important role in the pathogenesis of endothelial dysfunction. Aim of the present study was to evaluate the effect of metformin on endothelial function and insulin resistance, assessed by the homeostasis model (HOMA-IR, homeostasis model assessment-insulin resistance), in patients with MS.
methodsSixty-five subjects (37 men and 28 women, mean age 54 +/- 6 years) with MS were allocated to receive metformin 500 mg twice daily (n = 32) or placebo (n = 33) for 3 months. Before and after treatment we assessed endothelial function, using flow-mediated dilatation of the brachial artery, and HOMA-IR.
resultsPatients who received metformin demonstrated statistically significant improvement in endothelium-dependent vasodilation compared with those treated with placebo (from 7.4 +/- 2.1% to 12.4 +/- 1.9% vs. 7.3 +/- 2.5% to 6.9 +/- 2.7%, P = 0.0016, metformin vs. placebo respectively), without significant effect on endothelium-independent response to sublingual glyceryl trinitrate (P =0.32). Metformin improved insulin resistance compared with placebo group (HOMA-IR from 3.39 to 2.5 vs. 3.42 to 3.37; 26% reduction in HOMA-IR, P = 0.01). An association between the improvement in insulin resistance and the improvement in endothelial function (r = -0.58, P = 0.0016) was found.
conclusionMetformin improves both endothelial function and insulin resistance in patients with MS. These findings support the central role of insulin resistance in the development of endothelial dysfunction and the role of metformin for the treatment of patients with MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.